Comparison of multiple DNA adduct types in tumor adjacent human lung tissue: effect of cigarette smoking*
R. Godschalk1,
J. Nair1,4,
F.J. van Schooten2,
A. Risch1,
P. Drings3,
K. Kayser3,
H. Dienemann3 and
H. Bartsch1
1 German Cancer Research Center (DKFZ), Division of Toxicology and Cancer Risk Factors, Im Neuenheimer Feld 280, 69120 Heidelberg, Germany,
2 University of Maastricht, Department of Health Risk Analysis and Toxicology, Universiteitssingel 50, 6200 MD Maastricht, The Netherlands and
3 Thoraxklinik Heidelberg-Rohrbach, Amalienstraße 5, 69126 Heidelberg, Germany
 |
Abstract
|
---|
Cigarette smokers inhale a broad range of carcinogens derived from tobacco and its pyrolysis products, including free radicals, which induce oxidative stress and subsequent lipid peroxidation (LPO). Miscoding carcinogenDNA adducts are formed by cigarette smoke constituents and are thought to initiate lung carcinogenesis. The presence of various types of DNA damage was therefore analyzed in tumor adjacent uninvolved lung tissues of 13 smoking and 11 non-smoking operated lung cancer patients. O4-ethylthymidine (O4etT), 1,N6-ethenodeoxyadenosine (
dA) and 3,N4-ethenodeoxycytidine (
dC) were determined by immuno-enriched 32P-postlabeling. Polycyclic aromatic hydrocarbon (PAH)DNA adducts were measured as diagonal radioactive zones after nuclease P1 enriched 32P-postlabeling. Mean O4etT and PAHDNA adduct levels were higher in lung DNA of smokers than of non-smokers (O4etT/108 thymidine: 3.8 versus 1.6, P < 0.01; PAHDNA adducts/108 nucleotides: 11.2 versus 2.2, P < 0.01). Pulmonary ethenoDNA adduct levels did not differ between smokers and non-smokers, but large inter-individual variations were observed (80- and 250-fold differences for
dA and
dC, respectively). As all smokers (except one) refrained from smoking at least for 1 week before surgery, our results demonstrate the persistence of O4etT and PAHDNA adducts in human lung. A positive correlation obtained between O4etT and PAHDNA adducts (R = 0.65, P < 0.01) suggests that both adducts are formed from cigarette smoke as the main exposure source. We conclude that in addition to the DNA adducts derived from PAH and tobacco-specific nitrosamines, miscoding O4etT lesions are formed by cigarette smoke that contribute to the increased genomic instability and increased lung cancer risk in smokers.
Abbreviations: BPDE, benzo[a]pyrene-diol epoxide;
dA, 1,N6-ethenodeoxyadenosine;
dC, 3,N4-ethenodeoxycytidine; LPO, lipid peroxidation; NDEA, N-nitrosodiethylamine; O4etT, O4-ethylthymidine; PAH, polycyclic aromatic hydrocarbons; PEI, polyethyleneimine
 |
Introduction
|
---|
Cigarette smoking is causally associated with the development of pre-neoplastic biochemical changes in human lung (1) and lung cancer (2). It is hypothesized that the mechanism of tobacco smoke-induced lung cancer varies according to the location and histological type of the tumor. The deposition of cigarette smoke particulates containing polycyclic aromatic hydrocarbons (PAH) in the major lung bronchi probably initiates the formation of squamous cell carcinoma at that site. Many researchers have focused on the role of PAH-induced DNA damage in the induction of lung cancer (36). The reactive metabolite of the well studied benzo[a]pyrene, benzo[a]pyrene-diol epoxide (BPDE), was found to bind to a specific hotspot in the p53-gene, which has been found to be frequently mutated in human lung cancer (3) and aromaticDNA adduct levels were found to correlate with lung cancer risk in a recent prospective molecular epidemiological study (4).
On the basis of decreasing concentrations of tar that contains benzo[a]pyrene and other PAH, and increasing levels of alkylating compounds such as tobacco-specific nitrosamines (TSNA) in cigarette smoke, it is plausible that alkylating carcinogens are partially responsible for the rise in the incidence of lung adenocarcinoma, which has now surpassed squamous cell carcinoma as the leading type of lung cancer (7). Tobacco smoke-derived alkylating compounds covalently bind to DNA in the lung and their mutagenic potency depends mainly on the position of binding within the four DNA bases: O-substitution by alkylating agents results in relevant DNA adducts in terms of mutagenesis and carcinogenesis, including O6-alkylguanine and O4-alkylthymine (8). Cigarette smoke contains ethylating compounds, such as N-nitrosodiethylamine (NDEA) and hitherto uncharacterized ethylating agents, since increased levels of N-ethylated DNA bases have been reported in urine of smokers as compared with non-smokers (911). Animal studies indicated that after exposure to ethylating compounds, O4-ethylthymidine (O4etT) is initially formed in very low levels, but is poorly repaired and thus accumulates to biologically relevant levels (12). Our newly developed method for the detection of O4etT made it now possible to study the formation of O4etT in human lung of smoking and non-smoking subjects (13).
The role of continuous exposure to tobacco smoke-derived free radicals in the onset or progression of lung cancer still needs further attention. Free radicals may enhance lipid peroxidation (LPO) in the lung by which reactive unsaturated aldehydes are generated (14). Further oxidation of the aldehyde 4-hydroxy-2-nonenal leads to the formation of 2,3-epoxy-4-hydroxynonanal, a bifunctional alkylating agent which can react with DNA to yield etheno-DNA adducts, including 1,N6-ethenodeoxyadenosine (
dA) and 3,N4-ethenodeoxycytidine (
dC). EthenoDNA adducts are highly miscoding lesions in mammalian cells and are thought to initiate the carcinogenic process through specific point mutations, as shown for the known carcinogen vinyl chloride (15). However, no information is available yet on the presence and levels of these ethenoDNA adducts in human lung.
In the present study, a direct comparison has been made between the persistence of DNA adducts by different classes of tobacco smoke-derived carcinogens in lung tissue of smoking and non-smoking lung tumor patients. We investigated by 32P-postlabeling, the formation of aromaticDNA adducts, O4etT, and adducts formed by LPO products,
dA and
dC in tumor adjacent, uninvolved lung tissue of smoking and non-smoking operated lung tumor patients.
 |
Materials and methods
|
---|
Characteristics of study-subjects
Adjacent non-tumorous lung tissues from 13 smoking and 11 non-smoking lung tumor patients (mean age 61 ± 9, 15 male/nine female) were collected at surgery for lung tumor resection. Histological types of lung cancer were determined by the hospital pathologists. Tissue samples were frozen in liquid nitrogen immediately after surgery, and stored at 80°C. Smoking information was obtained from the patient by questionnaire. The study was approved by the ethical committee of the University of Heidelberg (no. 182/96). The overall characteristics of the study subjects are given in Table I
.
DNA isolation procedure from human lung samples
Approximately 80 mg of tissue was homogenized in lysis-buffer (DNA-isolation kit supplied by Qiagen, Hilden, Germany) using a polytron homogenizer (15 000 r.p.m. for ~30 s). Proteinase K and RNases were added, followed by a 2 h incubation at 50°C. Subsequently, DNA was isolated using Qiagen columns according to the manufacturers protocol with the following modification of the supplied elution buffer; pH was set to 7.4 and the NaCl concentration was increased to 1.4 M. DNA was precipitated by the addition of 0.7 volume isopropanol, collected by centrifugation, washed twice with 70% ethanol and dried in vacuo. Before analysis, DNA was redissolved in water and quantified by spectrophotometry at 260 nm.
Adduct analyses by 32P-postlabeling
O4-ethylthymidine. O4etT was analyzed according to Godschalk et al. (13). Briefly, DNA (25 µg) was digested into nucleotide monophosphates by micrococcal nuclease and spleen phosphodiesterase followed by immunoprecipitation of O4etT with saturated ammonium sulfate using the specific antibody ER-01. Normal nucleotides were quantified by HPLC-UV analysis of the supernatants after adduct precipitation. The antibodyadduct interaction product was collected by centrifugation, redissolved in 400 µl water and transferred into a microcon centrifugation filter (MY-50, molecular weight cut-off: 50 000 Da), which retains the antibodyadduct complex. Filters were washed five times with water and the remnants collected by inversion of the filter and short centrifugation (10 000 r.p.m. for 5 min). Proteins were precipitated by the addition of 500 µl cold ethanol and the supernatants were dried and stored at 80°C. Internal standard (800 attomol
dA) and 4 µl kinase buffer were added to the dried enriched samples. After addition of 2 µl of [
-32P]ATP (20 µCi), 10 U T4-PNK were added and the mixture was incubated for 2 h at 37°C. Another 10 U T4-PNK were added after 1 h of incubation. Polyethyleneimine (PEI) minicolumns were prepared by filling 2.5 mg PEI into a 200 µl pipet-tip closed with a small frit. The labeled samples were pipetted on top of the PEI and centrifuged for 5 min at 10 000 r.p.m. at 4°C. The labeled adducts were eluted with 5x25 µl 1 M acetic acid, whereas excess ATP bound to the PEI. The eluent was injected into a C18-HPLC with online detection of radioactivity. The mobile phase consisted of 100 mM ammonium formate pH 7.5 with 5% MeOH during the first 12 min at a flow rate of 1 ml/min. Then, the methanol concentration was increased to 20% over an 8 min time period (from 12 to 20 min) and further increased to 50% over a period of 10 min (from 20 to 30 min). The internal standard eluted at 17 min and O4etT-5' 32P-monophosphate at 22 min, whereas residual normal nucleotides eluted before 12 min as shown in Figure 1A
(sample) and D (standard).

View larger version (79K):
[in this window]
[in a new window]
|
Fig. 1. Typical DNA adduct profiles for respectively O4-ethylthymidine (A), ethenoDNA adducts (B) and aromaticDNA adducts (C). (DF) Represent the corresponding standards.
|
|
1,N6-ethenodeoxyadenosine (
dA), 3,N4-ethenodeoxycytidine (
dC).
dA and
dC were analyzed in DNA by immunoaffinity/32P-postlabeling (15). In brief, 25 µg of DNA was hydrolyzed to nucleotide 3'-monophosphates using micrococcal nuclease and spleen phosphodiesterase. Normal nucleotides were quantified by high-performance liquid chromatography of part of the digest and the adducts were enriched on immunoaffinity columns prepared from the monoclonal antibodies EM-A-1 (
dA) and EM-C-1 (
dC). The antibodies used in this study were provided by M.Rajewsky (Institute of Cell Biology, University of Essen, Essen, Germany); their characteristics have been reported previously. The adducts and the internal standard deoxyuridine 3'-monophosphate were labeled with [
-32P]ATP (>5000 Ci/mmol) and T4 polynucleotide kinase (Amersham Buchler, Braunschweig, Germany and Pharmacia Biotech, Freiburg, Germany, respectively). The adducts were resolved on polyethyleneimine-TLC plates using two-directional chromatography [D1 = 1 M acetic acid (pH 3.5), D2 = saturated ammonium sulfate (pH 3.5)]. After autoradiography, the adduct spots and the internal standard were marked, cut, and the radioactivity was measured in a liquid scintillation counter. The absolute adduct levels were quantified using standards, and the relative adduct level per parent nucleotides was determined with the amount of deoxycytidine (dC) and deoxyadenosine (dA) obtained from high-performance liquid chromatography analysis of normal nucleotides obtained from the DNA digest. Typical chromatograms are shown in Figure 1B
(sample) and E (standard).
AromaticDNA adducts.
DNA (~10 µg) was digested into nucleotide monophosphates and treated with nuclease P1 for 40 min at 37°C (16). Then, nucleotides were 5'-labeled with 32P using T4-polynucleotide kinase (5.0 U) for 30 min at 37°C. Radiolabeled adduct nucleotide biphosphates were separated by chromatography on PEI-cellulose sheets (Macherey Nagel, Germany). The following solvent systems were used: D1, 1 M NaH2PO4 pH 6.5; D2, 8.5 M urea, 5.3 M lithium formate pH 3.5; D3, 1.2 M lithium chloride, 0.5 M Tris, 8.5 M urea pH 8.0; D4, 1.7 M NaH2PO4 pH 6.0. In each experiment, three standards of [3H]BPDE modified DNA with known modification levels (1/107, 108, 109 nucleotides) were run in parallel for quantification purposes. Quantification was performed by using phosphor imaging technology (Molecular Dynamics, Sunnyvale). Detection limits of <0.1 adducts/108 nucleotides were obtained for [3H]BPDEDNA. A typical chromatogram is shown in Figure 1C
(sample) and F (standard). Adducts were quantified as total aromaticDNA adducts (total radioactivity) and as putative BPDEDNA adducts (radioactivity at chromatographic location of BPDEDNA).
Statistics
Data are presented as means (±SD). Non-parametric tests were used to assess statistical significances; the MannWhitney U-test was used to assess differences between DNA adduct levels in smokers and non-smokers and the Friedman test for paired samples was used to assess differences between the levels of various DNA adduct types. Adduct levels of samples in which no adducts were detectable, were arbitrarily set on half of the detection limit. Relationships between DNA adduct levels were determined by simple regression analysis. P < 0.05 was considered statistically significant.
 |
Results
|
---|
O4etT in human lung
O4etT reached detectable levels in 10 out of 13 smokers, but only in three out of 11 non-smokers (limit of detection is ~2 adducts/108 thymidines). O4etT levels were ~2.4-fold higher in smoking lung cancer patients as compared with non-smoking subjects (3.8 ± 2.1 O4etT/108 thymidines versus 1.6 ± 1.3, respectively, P = 0.003, Table II
). Overall O4etT levels ranged from <2.0 to 8.6 adducts/108 normal thymidines. Levels of O4etT in human lung were not found to be related to age, gender, histological tumor-type or tumor-stage.
View this table:
[in this window]
[in a new window]
|
Table II. Relative levels of PAHDNA adducts, O4-ethylthymidine and ethenoDNA adducts in human lung, expressed either as adducts per 108 parent nucleotides or adducts per 108 total nucleotides (mean ± SD and range)
|
|
PAHDNA adducts
AromaticDNA adduct profiles showed diagonal radioactive zones (DRZ) in all smokers except one, which is found to be typical for exposure to complex chemical mixtures. Faint DRZs were found in non-tumorous tissue of five out of 11 non-smoking subjects. Total aromaticDNA adduct levels were significantly higher in smoking lung cancer patients as compared with non-smoking patients (11.2 ± 7.8 adducts/108 nucleotides and 2.2 ± 2.2, respectively, P = 0.001, Table II
). A positive correlation was observed between aromaticDNA adducts and O4etT, indicating that both were formed from the same source of exposure, i.e. cigarette smoke (r = 0.66, P < 0.01, Figure 2
, smokers and non-smokers combined). This relationship was also found after exclusion of non-smokers from the analysis (r = 0.54, P = 0.05). To get an impression of the BPDEDNA adduct level, DNA adducts that migrated at the position of BPDEDNA were additionally quantified. Putative BPDEDNA adduct levels were 1.5 ± 1.0/108 nucleotides in smoking subjects and 0.2 ± 0.2 in non-smokers (P < 0.001), which is most probably an overestimation of the actual BPDEDNA adduct level, because other adducts may co-migrate during TLC.

View larger version (16K):
[in this window]
[in a new window]
|
Fig. 2. Correlation between O4-ethylthymidine and aromaticDNA adducts in human lung of smokers and non-smokers (R = 0.66, P < 0.01). (Insert) Correlation between O4-ethylthymidine and putative BPDEDNA adducts (R = 0.64, P < 0.01).
|
|
EthenoDNA adducts in human lung
dA and
dC levels were not influenced by smoking behavior (Table II
), but were highly interrelated (R = 0.76, P < 0.001), suggesting that both adduct types were formed by similar pathways. Median
dA levels were 9.2 adducts/109 parent nucleotides (range 2.6146) and 9.4 (range 2.456.5) in non-smokers and smokers, respectively. Median
dC levels were 19.7/109 parent nucleotides (range 1.6395.5) and 9.8 (range 5.880.9) in non-smokers and smokers, respectively. Large inter-individual variations were observed;
dA levels ranged from 1.8 to 146.0 adducts/109 parent nucleotides (80-fold difference), whereas
dC levels ranged from 1.6 to 395.5 adducts/109 parent nucleotides (250-fold difference). Interestingly, these inter-individual variations were much higher in non-smokers (56- and 250-fold for
dA and
dC, respectively) than in smokers (31- and 19-fold for
dA and
dC, respectively). EthenoDNA adduct levels were not related to age, gender, histological tumor-type or tumor-stage.
Adduct abundancy
For reasons of comparison, the relative adduct levels of all adduct types were calculated as adducts per total nucleotides (Table II
). O4etT levels were 0.5 ± 0.4 adducts/108 nucleotides and 1.2 ± 0.6 for non-smokers and smokers, respectively. Quantification of aromaticDNA adducts that migrated at the position of BPDEDNA in smokers resulted in mean levels of 1.5 ± 1.0 adducts/108 nucleotides (range <0.12.6), which was not statistically different as compared with the levels of O4etT in the same individuals (range 0.62.5). When
-DNA adduct levels were also expressed as adducts per 108 total nucleotides,
dA levels were found to be 1.0 ± 1.6 in non-smokers (range 0.14.3) and 0.5 ± 0.5 in smokers (range 0.11.5), which was different from the levels of O4etT and putative BPDEDNA in smokers, but not in non-smokers. For
dC similar results were found (Table II
). In all smokers and non-smokers, BPDEDNA like adducts, O4etT and ethenoDNA adducts were detected at similar levels in lung DNA (Table II
).
 |
Discussion
|
---|
Several studies indicated that the formation of PAHDNA adducts, particularly BPDEDNA, in human lung is involved in tobacco smoke-induced lung carcinogenesis (3,4). In the present study total aromaticDNA adducts and putative BPDEDNA adducts were found to be higher in smokers than in non-smokers by 32P-postlabeling. In other studies on PAHDNA adducts in human lung, similar results were obtained by 32P-postlabeling (5,6,17,18), but the quantitative aspects should be regarded with some caution, because of uncertainties in the efficiency of 32P-labeling, recovery and identification of adducts. Nonetheless, putative BPDEDNA adduct levels as determined in the present study are comparable with those levels reported for human lung using an HPLC-fluorescence detection methodology, with which specific BPDEDNA adducts can be detected and quantified (19,20).
Our newly developed methodology to measure O4etT in small quantities of DNA enabled the analysis of human lung samples. O4etT levels were significantly increased in smokers as compared with non-smokers and the levels correlated with aromaticDNA adduct levels, indicating that both originate from cigarette smoke as the main source of exposure. Although active removal of O4etT from human DNA was reported (21), the repair mechanisms have not yet been elucidated. The current evidence suggests that O4etT is only poorly repaired by O6-alkylguanine-DNA-alkyltransferase (12). Nucleotide excision repair seems to be involved (12,22), which is in agreement with the observed close relationship between O4etT and PAHDNA adducts in the present study, as bulky PAHDNA adducts are also repaired by nucleotide excision repair.
Direct comparison of O4etT and BPDEDNA adducts normalized to total nucleotides, showed that both adducts were equally abundant in lung DNA of smokers (Table II
), and therefore the highly promutagenic O4etT may contribute equally to the increased genomic instability and increased cancer risk in smokers. Ethylating compounds are rare as environmental contaminants, but they were undoubtedly found in cigarette smoke (such as NDEA, 0.128 ng/cigarette; 23). Increased urinary excretion of N-ethylated adenine has been reported for smokers as compared with non-smokers (911) and the measurement of O4etT was therefore expected to offer a highly specific DNA modification to assess exposure to tobacco smoke. Until now, other types of carcinogenDNA adducts have been used for this purpose, but due to their ubiquitous presence in the environment it could not be established from what source the carcinogens originate. For example, PAH occur in cigarette smoke, but can also be found in large quantities in food products. Oral and inhalation exposure to these compounds might both lead to detectable DNA adducts in lung tissue (24), and are thus thought to be unspecific for cigarette smoke. In the present study, we also have detected O4etT and PAHDNA adducts in lung DNA of non-smokers. The source of these background levels could be the environment, environmental tobacco smoke or both. We could neither confirm nor exclude a role of ETS, due to limited exposure data of these patients. NDEA levels were found to be up to 40 times higher in side stream cigarette smoke as compared with main stream smoke (7). Also, in studies on the urinary excretion of ethylated DNA bases (911) and in a study on the ethylation of hemoglobin (25), background levels were observed in non-smoking subjects. Recently, the ethylation and methylation of N-terminal valine of hemoglobin was investigated (25) and a difference was found between smokers and non-smokers for ethyl-valine but not for methyl-valine. Similar results were reported for O4-ethyl- and O4-methyl-thymidine in human lung DNA (26). These observations indicate that measuring DNA ethylation is more specific for cigarette smoke exposure than methylation.
Surprisingly, no effect of smoking was found on the formation of ethenoDNA adducts, which is not in line with previous studies that found slightly elevated 8-hydroxy-deoxyguanosine levels (~1.5-fold) as marker for oxidative stress in cigarette smokers (27). Most subjects in the present study reported to have stopped smoking at least 1 week before surgery. Therefore, effective DNA repair of ethenoDNA adducts may explain why we did not see a difference between smokers and non-smokers. Our data also indicate that lung tissue is well protected against LPO induced by exogenous radicals, because the levels of background ethenoDNA adducts as reported in this study, were lower as compared with the levels reported for other human tissues, such as colon-epithelium, liver, pancreas, oesophagus and leucocytes (14). Still, in some individuals high levels of ethenoDNA adducts were found, which could be due to increased formation or high persistence (e.g. poor repair) of the adducts. Individuals may significantly differ in their effectivity for removal of
dA and
dC, because the
dC:
dA ratio ranged from 0.1 to 7.5 (data not shown);
dA is repaired by 3-methyladenine DNA glycosylase, whereas
dC is repaired by a mismatch specific thymidine-DNA glycosylase (28). Highest ethenoDNA adduct levels were found in non-smoking lung cancer subjects with low levels of PAHDNA adducts or O4etT, suggesting that
-DNA adducts may be involved in the onset or progression of lung cancer in non-smoking subjects. However, more studies are necessary to find biological reasons and implications of the large inter-individual differences in the levels of etheno-bridged DNA bases.
Table III
shows a brief summary of major DNA adduct types detected in human lung DNA. Studies reporting adduct levels in both smokers and non-smokers were included. Though higher adduct levels were reported for 8-hydroxy-dG in human lung, only DNA adducts by ethylating compounds (i.e. O4etT and O6-ethyl-dG), bulky PAHDNA adducts, BPDEDNA and the HPB-releasing adducts were found to be >2-fold increased (range 214-fold) in smokers as compared with non-smokers, suggesting that these adduct types are derived from tobacco smoke carcinogens and can be used as biomarkers for exposure to cigarette smoke. Overall cumulative levels of these adducts were 48.7 and 20.1 base modifications/108 nucleotides for smokers and non-smokers, respectively. We conclude that in addition to DNA adducts derived from PAH and TSNA (29), miscoding O4etT lesions are formed by cigarette smoke that contribute to the increased genomic instability and lung cancer risk in smokers.
View this table:
[in this window]
[in a new window]
|
Table III. Literature data and results from this study on levels of various DNA adduct types (number of adducts per 108 nucleotidesa) in non-tumorous lung tissue of smokers and non-smokers
|
|
 |
Notes
|
---|
* This article is dedicated to Harald zur Hausen on the occasion of his retirement as head of the German Cancer Research Center with gratitude and appreciation for 20 years of leadership. 
4 To whom correspondence should be addressed Email: j.nair{at}dkfz.de 
 |
Acknowledgments
|
---|
Roger Godschalk was recipient of a EU-Marie Curie fellowship. The authors would like to thank Marcel van Herwijnen (Maastricht University, Maastricht, The Netherlands) and Christel Ditrich (German Cancer Research Center, Heidelberg, Germany) for their technical assistance.
 |
References
|
---|
- Kayser,K., Andre,S., Bovin,N.V., Zeng,F.-Y. and Gabius,H.-J. (1997) Preneoplasia-associated expression of calcyclin and of binding sites for synthetic blood group A/H trisaccharide-exposing neoglycoconjugates in human lung. Cancer Biochem. Biophys., 15, 235243.[ISI][Medline]
- Hecht,S.S. (2002) Cigarette smoking and lung cancer: chemical mechanisms and approaches to prevention. Lancet Oncol., 3, 461469.[ISI][Medline]
- Denissenko,M.F., Pao,A., Tang,M. and Pfeifer,G.P. (1996) Preferential formation of benzo[a]pyrene adducts at lung cancer mutational hotspots in P53. Science, 274, 430432.[Abstract/Free Full Text]
- Tang,D., Phillips,D.H., Stampfer,M. et al. (2001) Association between carcinogen-DNA adducts in white blood cells and lung cancer risk in the physicians health study. Cancer Res., 61, 67086712.[Abstract/Free Full Text]
- Ryberg,D., Hewer,A., Phillips,D.H. and Haugen,A. (1994) Different susceptibility to smoking-induced DNA damage among male and female lung cancer patients. Cancer Res., 54, 58015803.[Abstract]
- Schoket,B., Phillips,D.H., Kostic,S. and Vincze,I. (1998) Smoking-associated bulky DNA adducts in bronchial tissue related to CYP1A1 MspI and GSTM1 genotypes in lung patients. Carcinogenesis, 19, 841846.[Abstract]
- Hecht,S.S. (1999) Tobacco smoke carcinogens and lung cancer. J. Natl Cancer Inst., 91, 11941210.[Abstract/Free Full Text]
- Barbin,A. and Bartsch,H. (1989) Nucleophilic selectivity as a determinant of carcinogenic potency (TD50) in rodents: a comparison of mono- and bi-functional alkylating agents and vinyl chloride metabolites. Mutat. Res., 215, 95106.[ISI][Medline]
- Prevost,V. and Shuker,D.E. (1996) Cigarette smoking and urinary 3-alkyladenine excretion in man. Chem. Res. Toxicol., 9, 439444.[ISI][Medline]
- Prevost,V., Shuker,D.E., Friesen,M.D., Eberle,G., Rajewsky,M.F. and Bartsch,H. (1993) Immunoaffinity purification and gas chromatography-mass spectrometric quantification of 3-alkyladenines in urine: metabolism studies and basal excretion levels in man. Carcinogenesis, 14, 199204.[Abstract]
- Eberle,G., Glüsenkamp,K.H., Drosdziok,W. and Rajewsky,M.F. (1990) Monoclonal antibodies for the specific detection of 3-alkyladenines in nucleic acids and body fluids. Carcinogenesis, 11, 17531759.[Abstract]
- Bronstein,S.M., Skopek,T.R. and Swenberg,J.A. (1992) Efficient repair of O6-ethylguanine, but not O4-ethylthymine or O2-ethylthymine, is dependent upon O6-alkylguanine-DNA alkyltransferase and nucleotide excision repair activities in human cells. Cancer Res., 52, 20082011.[Abstract]
- Godschalk,R.W.L., Nair,J., Kliem,C., Wiessler,M., Bouvier,G. and Bartsch,H. (2002) Modified immuno-enriched 32P-HPLC assay for the detection of O4-ethylthymidine in human biomonitoring studies. Chem. Res. Tox., 15, 433437.[ISI][Medline]
- Bartsch,H. and Nair,J. (2000) New DNA based biomarkers for oxidative stress and cancer chemoprevention studies. Eur. J. Cancer, 36, 12291234.[ISI][Medline]
- Nair,J., Barbin,A., Guichard,Y. and Bartsch,H. (1995) 1,N6-ethenodeoxyadenosine and 3,N4-ethenodeoxycytine in liver DNA from humans and untreated rodents detected by immunoaffinity/32P-postlabelling. Carcinogenesis, 16, 613617.[Abstract]
- Godschalk,R.W.L., Maas,L.M., Van Zandwijk,N., Van `t Veer,L.J., Breedijk,A., Borm,P.J.A., Verhaert,J., Kleinjans,J.C.S. and Van Schooten,F.J. (1998) Differences in aromatic-DNA adduct levels between alveolar macrophages and subpopulations of white blood cells from smokers. Carcinogenesis, 19, 819825.[Abstract]
- Phillips,D.H., Hewer,A., Martin,C.N., Garner,R.C. and King,M.M. (1988) Correlation of DNA adduct levels in human lung with cigarette smoking. Nature, 336 (6201), 790792.[ISI][Medline]
- Phillips,D.H., Schoket,B., Hewer,A., Bailey,E., Kostic,S. and Vincze,I. (1990) Influence of cigarette smoking on the levels of DNA adducts in human bronchial epithelium and white blood cells. Int. J. Cancer, 46, 569575.[ISI][Medline]
- Alexandrov,K., Rojas,M., Geneste,O., Castegnaro,M., Camus,A.M., Petruzzelli,S., Giuntini,C. and Bartsch,H. (1992) An improved fluorometric assay for dosimetry of benzo(a)pyrene diol-epoxide-DNA adducts in smokers lung: comparisons with total bulky adducts and aryl hydrocarbon hydroxylase activity. Cancer Res., 52, 624853.[Abstract]
- Rojas,M., Alexandrov,K., Cascorbi,I. et al. (1998) High benzo(a)pyrene diol-epoxide DNA adduct levels in lung and blood cells from individuals with combined CYP1A1 MspI/MspI-GSTM1*0/*0 genotypes. Pharmacogenetics, 8, 109118.[ISI][Medline]
- Wani,A.A., Wani,G. and DAmbrosio,S.M. (1990) A human DNA repair activity specific for O4-ethylthymine: identification and partial characterization. Carcinogenesis, 11, 14191424.[Abstract]
- Klein,J.C., Bleeker,M.J., Roelen,H.C. et al. (1994) Role of nucleotide excision repair in processing of O4-alkylthymines in human cells. J. Biol. Chem., 269, 2552125528.[Abstract/Free Full Text]
- Hoffmann,D. and Wynder,E.L. (1986) Chemical constituents and bioactivity of tobacco smoke. In Zaridze,D., Peto,R. (eds) Tobacco, A Major International Health Hazard. IARC Scientific Publications, IARC, Lyon, No. 74 pp. 145166.
- Godschalk,R.W., Moonen,E.J., Schilderman,P.A., Broekmans,W.M., Kleinjans,J.C. and Van Schooten,F.J. (2000) Exposure-route-dependent DNA adduct formation by polycyclic aromatic hydrocarbons. Carcinogenesis, 21, 8792.[Abstract/Free Full Text]
- Carmella,S.G., Chen,M., Villalta,P.W., Gurney,J.G. and Hecht,S.S. (2002) Ethylation of N-terminal valine of hemoglobin in smokers and non-smokers. Proc. Am. Assoc. Cancer Res., Abstract no. 279.
- Kang,H., Konishi,C., Bartsch,H., Kuroki,T. and Huh,N. (1995) Detection of smoking related O4-ethylthymine in human lung tissues. Proc. Am. Assoc. Cancer Res., Abstract no. 810.
- Lee,H.C., Lim,M.L., Lu,C.Y., Liu,V.W., Fahn,H.J., Zhang,C., Nagley,P. and Wei,Y.H. (1999) Concurrent increase of oxidative DNA damage and lipid peroxidation together with mitochondrial DNA mutation in human lung tissues during aging-smoking enhances oxidative stress on aged tissues. Arch. Biochem. Biophys., 362, 309316.[ISI][Medline]
- Saparbaev,M. and Laval,J. (1999) Enzymology of the Repair of Etheno Adducts in Mammalian Cells and in Escherichia coli. IARC Scientific Publications, IARC, Lyon, 150, 249261.
- Hecht,S.S. (1999) DNA adduct formation from tobacco-specific N-nitrosamines. Mutat. Res., 424, 127142.[ISI][Medline]
- Blömeke,B., Greenblatt,M., Van Doan,D., Bowman,E., Murphy,S.E., Chen,C.C., Kato,S. and Shields,P.G. (1996) Distribution of 7-alkyl-2'-deoxyguanosine adduct levels in human lung. Carcinogenesis, 17, 741748.[Abstract]
- Wilson,V.L., Weston,A., Manchester,D.K. et al. (1989) Alkyl and aryl carcinogen adducts detected in human peripheral lung. Carcinogenesis, 10, 21492153.[Abstract]
- Foiles,P.G., Akerkar,S.A., Carmella,S.G., Kagan,M., Stoner,G.D., Resau,J.H. and Hecht,S.S. (1991) Mass spectrometric analysis of tobacco-specific nitrosamine-DNA adducts in smokers and nonsmokers. Chem. Res. Toxicol., 4, 364368.[ISI][Medline]
- Lin,D., Lay,J., Bryant,S.B., Malaveille,C., Friesen,M., Bartsch,H., Lang,N.P. and Kadlubar,F.F. (1994) Analysis of 4-aminobiphenyl-DNA adducts in human urinary bladder and lung by alkaline hydrolysis and negative ion gas chromatography-mass spectrometry. Environ. Health. Perspect., 102 (suppl 6), 1116.
- Asami,S., Manabe,H., Miyake,J., Tsurudome,Y., Hirano,T., Yamaguchi,R., Itoh,H. and Kasai,H. (1997) Cigarette smoking induces an increase in oxidative DNA damage, 8-hydroxyguanosine, in a central site of the human lung. Carcinogenesis, 18, 17631766.[Abstract]
Received August 6, 2002;
revised October 7, 2002;
accepted October 8, 2002.